The Recall Desk

FDA (Drugs) recall action 79955

Mylan Pharmaceuticals Inc. recalled 2 products on 2018-05-30

The FDA (Drugs) publishes a recall like this one as 2 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 2 pages.

Products
2
Announced
2018-05-30
Critical
0
Units
20,329

Why these products were recalled

CGMP Deviations

The agency’s own wording, quoted from the enforcement report.

The unit total adds up the quantities the agency stated for each product. Where a product record gave no figure, or gave a weight rather than a count, it contributes nothing — so the real total is at least this, never less.

States named across these recalls

1–2 of 2

  • HighFDA (Drugs)··2018-05-30

    Mylan Recalls Loxapine Capsules Due to Manufacturing Deviations

    Mylan Pharmaceuticals is recalling 8,679 bottles of Loxapine Capsules 25 mg due to CGMP deviations. The product was distributed throughout the United States and Puerto Rico.

    Product
    Loxapine Capsules, USP 25 mg, Rx Only, 100-count bottles, NDC 0378-7025-01
    Category
    Distribution
    1 state
  • HighFDA (Drugs)··2018-05-30

    Mylan Recalls Loxapine Capsules Due to Manufacturing Deviations

    Mylan Pharmaceuticals is voluntarily recalling 11,650 bottles of Loxapine Capsules 50 mg due to Current Good Manufacturing Practice (CGMP) deviations.

    Product
    Loxapine Capsules, USP 50 mg, Rx Only, 100-count bottles, NDC 0378-7050-01
    Category
    Distribution
    1 state